Emergent BioSolutions Sets Q3 Revenue Guidance at $110M-$130M and Outlines Debt Reduction
EBS sits 46% above its 52-week low of $4.36.
Summary
Emergent BioSolutions disclosed Q3 revenue guidance of $110M-$130M and detailed $75M in Q3 bond repurchases plus a reauthorized $50M buyback program in an investor presentation.
Key Events · Earnings and Guidance · EBS
-
Q3 Revenue Guidance Set at $110M-$130M
First-time disclosure of Q3 revenue guidance of $110M-$130M, implying a sequential decline from Q2's $234.3M total revenues.
-
$75M Bond Repurchase in Q3
Company repurchased $75M aggregate principal of unsecured bonds in Q3, utilizing $68M of cash on hand.
-
$50M Share Repurchase Program Reauthorized
Board reauthorized a $50M share repurchase program through March 2027, with $37.5M remaining available after 1.9M shares repurchased YTD for $18M.
-
International Regulatory Approvals for ACAM2000
Received Saudi Food and Drug Authority approval for ACAM2000 and Singapore Health Sciences Authority approval to expand indication to include Mpox.
Analysis · EBS · Life Sciences
The investor presentation discloses Q3 revenue guidance of $110M-$130M for the first time, alongside material updates on debt reduction ($75M bond repurchase in Q3) and a reauthorized $50M share repurchase program. These disclosures come against a backdrop of a $180.2M Q2 loss and a revised full-year outlook that cut revenue guidance by roughly $75M at the midpoint. The new Q3 range implies a sequential decline from Q2's $234.3M in total revenues, reflecting the naloxone competitive pressures and restructuring headwinds management has flagged. The debt reduction and buyback authorization show management deploying cash to strengthen the balance sheet and return capital, but the lower revenue trajectory and ongoing restructuring costs remain the dominant narrative.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EBS was trading at $6.38 on NYSE in the Life Sciences sector, with a market capitalization of approximately $327.1M. The 52-week trading range was $4.36 to $14.06. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.